Buer L - Search Results

1

Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring.

Wiken TH, Høivik ML, Buer L, Warren DJ, Bolstad N, Moum BA, Anisdahl K, Småstuen MC, Medhus AW. Wiken TH, et al. Among authors: buer l. Scand J Gastroenterol. 2023 Jul-Dec;58(8):863-873. doi: 10.1080/00365521.2023.2176252. Epub 2023 Feb 17. Scand J Gastroenterol. 2023. PMID: 36799155 Free article.

2

Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study.

Buer LC, Moum BA, Cvancarova M, Warren DJ, Medhus AW, Høivik ML. Buer LC, et al. J Crohns Colitis. 2017 Mar 1;11(3):297-304. doi: 10.1093/ecco-jcc/jjw166. J Crohns Colitis. 2017. PMID: 27660339

3

Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease?

Buer L, Høivik ML, Medhus AW, Moum B. Buer L, et al. Dig Dis. 2017;35(1-2):74-82. doi: 10.1159/000449087. Epub 2017 Feb 1. Dig Dis. 2017. PMID: 28147370

4

Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series.

Buer LCT, Høivik ML, Warren DJ, Medhus AW, Moum BA. Buer LCT, et al. Inflamm Bowel Dis. 2018 Apr 23;24(5):997-1004. doi: 10.1093/ibd/izx110. Inflamm Bowel Dis. 2018. PMID: 29668901

5

Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.

Høivik ML, Buer LCT, Cvancarova M, Warren DJ, Bolstad N, Moum BA, Medhus AW. Høivik ML, et al. Among authors: buer lct. Scand J Gastroenterol. 2018 Jun;53(6):692-699. doi: 10.1080/00365521.2018.1463391. Epub 2018 May 31. Scand J Gastroenterol. 2018. PMID: 29852793

6

Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort.

Buer LCT, Moum BA, Cvancarova M, Warren DJ, Bolstad N, Medhus AW, Høivik ML. Buer LCT, et al. Scand J Gastroenterol. 2019 Jan;54(1):41-48. doi: 10.1080/00365521.2018.1548646. Epub 2019 Jan 16. Scand J Gastroenterol. 2019. PMID: 30650312

7

Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study.

Wiken TH, Høivik ML, Anisdahl K, Buer L, Warren DJ, Bolstad N, Hagen M, Moum BA, Medhus AW. Wiken TH, et al. Among authors: buer l. Crohns Colitis 360. 2024 Feb 26;6(1):otae013. doi: 10.1093/crocol/otae013. eCollection 2024 Jan. Crohns Colitis 360. 2024. PMID: 38544907 Free PMC article.

8

Comparing Bariatric Surgery Patients Who Desire, Have Undergone, or Have No Desire for Body Contouring Surgery: a 5-Year Prospective Study of Body Image and Mental Health.

Buer L, Kvalem IL, Bårdstu S, Mala T. Buer L, et al. Obes Surg. 2022 Sep;32(9):2952-2959. doi: 10.1007/s11695-022-06117-6. Epub 2022 Jun 23. Obes Surg. 2022. PMID: 35739416 Free PMC article.

9

The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed.

Frafjord A, Buer L, Hammarström C, Aamodt H, Woldbæk PR, Brustugun OT, Helland Å, Øynebråten I, Corthay A. Frafjord A, et al. Among authors: buer l. Front Immunol. 2021 Nov 18;12:764596. doi: 10.3389/fimmu.2021.764596. eCollection 2021. Front Immunol. 2021. PMID: 34868011 Free PMC article.

10

Appreciating contributions more than celebrating resilience: Reflections on the disclosure of substance use in Appalachia.

Clapp L, Conner S, Fonseca D, Jones C, Williams M, Buer LM. Clapp L, et al. Among authors: buer lm. Int J Drug Policy. 2021 Dec;98:103277. doi: 10.1016/j.drugpo.2021.103277. Epub 2021 May 27. Int J Drug Policy. 2021. PMID: 34053825

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16 results

Search Page

Filters